drugset / Trial / NCT00927758

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758

Phase 2 Completed 105 enrolled Sandoz
RandomizedCrossoverQuadruple-blindTreatment

Summary

To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.

Timeline

Start
2009-06
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 100 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 250 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 500 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled

Indications